Bio-Path Holdings, Inc. · OTC:BPTH

Bio-Path — TIDES 2015

19 slides from Bio-Path's conference presentation, May 2015

  1. Slide 1: Efficient systemic delivery of oligonucleotides by a neutral lipid technology

    Slide 1: Efficient systemic delivery of oligonucleotides by a neutral lipid technology

    Efficient systemic delivery of oligonucleotides by a neutral lipid technology Peter Nielsen, CEO TIDES 2015 “A New Paradigm in Drug Delivery”

  2. Slide 2: Talk Overview

    Slide 2: Talk Overview

    Talk Overview  About Bio-Path Holdings  DNAbilize™ Technology  Acute Myeloid Leukemia  Growth Receptor Bound Protein 2 (GRB2)  Phase I Results of Liposomal Grb2 (L-Grb2)  Future plans for L-Grb2  Summary 2

  3. Slide 3: Bio-Path Overview

    Slide 3: Bio-Path Overview

    Bio-Path Overview  Oncology focused pharmaceutical development company located in Bellaire, TX  Established in 2008 with technology licensed from the University of Texas MD Anderson Cancer Center  Listed on NASDAQ in March of 2014 as BPTH  Breakthrough science and cancer drugs  Unique, propriet

  4. Slide 4: DNAbilize Technology

    Slide 4: DNAbilize Technology

    DNAbilize™ Technology  Combination of a stabilizing nucleic acid backbone and neutral lipid delivery vehicle  P-ethoxy: uncharged analogues of phosphodiesters in which an ethyl group has been added to the non-bridging oxygen atom of the phosphate bonds.  Resistant against nuclease digestion  Res

  5. Slide 5: DNAbilize Technology

    Slide 5: DNAbilize Technology

    DNAbilize™ Technology  When combined with the neutral liposome, P-ethoxy DNA incorporate into the hydrophobic multi-lamellar structure in contrast to electrostatic interactions.  Neutral liposomes avoid the toxic effects of cationic liposomes on cell membranes by avoiding nonspecific interactions

  6. Slide 6: Acute Myeloid Leukemia: Fragile patient population

    Slide 6: Acute Myeloid Leukemia: Fragile patient population

    Acute Myeloid Leukemia: Fragile patient population  AML is the abnormal rapid growth of granulocyte precursors in the blood causing a drop in the other hematopoietic cell types  In 2014 there were ~19,000 cases of AML and ~10,000 deaths  Average age of diagnosis is 66 years old; older patients do

  7. Slide 7: Growth Receptor Bound Protein 2 (GRB2)

    Slide 7: Growth Receptor Bound Protein 2 (GRB2)

    Growth Receptor Bound Protein 2 (GRB2)  GRB2 protein is crucial to AML signaling cascades  GRB2 functions in RAS signaling by bridging Son of Sevenless (SOS) to activated tyrosine kinases including BCR-ABL, KIT, JAK2, CBL and FLT3.  FLT3 mutations occur in 30% of AML cases and over-expression of

  8. Slide 8: GRB2 signaling at tyrosine kinase receptors

    Slide 8: GRB2 signaling at tyrosine kinase receptors

    GRB2 signaling at tyrosine kinase receptors 8

  9. Slide 9: GRB2: first gene target using DNAbilize Technology

    Slide 9: GRB2: first gene target using DNAbilize Technology

    GRB2: first gene target using DNAbilize Technology Liposomal GRB2 (L-Grb2) disrupts RAS signaling Liposome L-Grb2 Empty L-Grb2 decreases GRB2 GRB2 expression by 70% b-actin Phosphorylated ERK ERK phosphorylation by 95% b-actin Phosphorylated AKT AKT phosphorylation by 90% b-actin 9

  10. Slide 10: L-Grb2 in Clinical Testing

    Slide 10: L-Grb2 in Clinical Testing

    L-Grb2 in Clinical Testing  Phase I clinical trial:  First 6 cohorts completed  Preliminary results show drug has been well tolerated in patients with AML, CML, and MDS with no signs of toxicity and signs of anti-leukemia activity  Safety segment of Phase II trial for Acute Myeloid Leukemia (AML

  11. Slide 11: Phase 1 Clinical Design

    Slide 11: Phase 1 Clinical Design

    Phase 1 Clinical Design Design: 3+3 dose escalating Participants: Adults ≥ 18 yo with refractory or relapsed AML, Ph+ CML, ALL, or MDS Doses Tested: 5, 10, 20, 40, 60 and 90 mg/m2 Treatment Plan: 2 doses per week for 4 weeks Inclusion / Patients Refractory Or Resistant to Current Therapies Exclusion

  12. Slide 12: Summary of Phase I Clinical Trial Results of L-Grb-2

    Slide 12: Summary of Phase I Clinical Trial Results of L-Grb-2

    Summary of Phase I Clinical Trial Results of L-Grb-2  AML, CML, ALL & MDS Patients Refractory Or Resistant to Current Therapies  Dose escalating, treatment cycle 8 doses Diagnosis Baseline Blast Nadir Off Treatment Cycles over 4 weeks CML 93% 82% 97% 0 AML 15% 2% 5% 5 Results through cohort 6 (90

  13. Slide 13: Response to Treatment for Select Patients 002 and 006

    Slide 13: Response to Treatment for Select Patients 002 and 006

    Response to Treatment for Select Patients 002 and 006  Patient 002: 32 year-old, Hispanic male with myeloid blast crisis of CML  Prior therapies consist of: ― Gleevec ― Dasatinib ― Nilotinib ― DCC-2036 ― Cytarabine/Fludarabine/ ― Dasatinib/Gemtuzumab ― PHA-739358 ― Clofarabine/Dasatinib  Patient

  14. Slide 14: Significant Results for Phase I Clinical Trial

    Slide 14: Significant Results for Phase I Clinical Trial

    Significant Results for Phase I Clinical Trial  Disease Stabilization in MDS and AML  Two patients with MDS, a 53-year-old male and a 72-year-old female, both achieved disease stabilization and continued therapy for 5 cycles before disease progression.  A 54-year-old HIV+ male with AML achieved s

  15. Slide 15: Preclinical Testing of L-Grb2 Combination Therapy

    Slide 15: Preclinical Testing of L-Grb2 Combination Therapy

    Preclinical Testing of L-Grb2 Combination Therapy  L-Grb2 combination therapy was tested in AML and CML cells to evaluate the effect of different dosing patterns:  L-Grb2 1st : Frontline 2nd versus Frontline 1st : L-Grb2 2nd  The results provided strong evidence that pre-treating leukemia cells w

  16. Slide 16: Overview of Plans For Phase II Clinical Trials of L-Grb2

    Slide 16: Overview of Plans For Phase II Clinical Trials of L-Grb2

    Overview of Plans For Phase II Clinical Trials of L-Grb2  We will conduct 3 Phase II clinical trials of L-Grb2 in AML, MDS, and CML as evaluated in the Phase I clinical trial  The current safety segment of the Phase II trial is in the process of evaluating 2 cohorts at 2 dose levels, 3 patients pe

  17. Slide 17: Development of L-Grb2 for Triple Negative and Inflammatory Breast Cancers

    Slide 17: Development of L-Grb2 for Triple Negative and Inflammatory Breast Cancers

    Development of L-Grb2 for Triple Negative and Inflammatory Breast Cancers  Bio-Path is developing L-Grb2 to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates  Breast cance

  18. Slide 18: Clinical Pipeline

    Slide 18: Clinical Pipeline

    Clinical Pipeline * *L-Grb2 for AML has received orphan-drug designation from the U.S. FDA 18

  19. Slide 19: Summary

    Slide 19: Summary

    Summary  Bio-Path has developed a unique antisense DNA + lipid delivery for systemic nucleic acid drug therapy called DNAbilize™ Technology  Our initial focus is on hematological malignancies with our lead target against GRB2, a bridge protein in tyrosine kinase signaling cascades  Our drug deliv

Source: Internet Archive copy of biopathholdings.com

More decks from Bio-Path Holdings, Inc.

All 11 Bio-Path decks